👋 Bye bye sotorasib #ESMO26 #LCSM

返回会议原文

返回会议

Dr. Antonio Calles 🫁🚭· @Tony_Calles · X·2026-10-26 00:16· 1 天前评分70

正文

暂无中文译文，显示英文原文。

👋 Bye bye sotorasib #ESMO26 #LCSM

12 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

引用@

Presented at #ESMO26: In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo 1 trial results: https://nej.md/4BiCvbk @myESMO

在 X 查看被引用的帖子

来源：Dr. Antonio Calles 🫁🚭 · x.com